Margarida Maia, PhD,  science writer—

Long-term treatment with Nucala (mepolizumab) — approved for use in EGPA, or eosinophilic granulomatosis with polyangiitis, the rarest type of ANCA-associated vasculitis — appears to be well tolerated by most patients, and was seen to reduce or even eliminate corticosteroid use. That’s according to new data from an…

A Phase 1 clinical trial assessing SC291, an experimental CAR T-cell therapy that Sana Biotechnology is developing for ANCA-associated vasculitis (AAV) and other autoimmune diseases, is recruiting patients at a number of sites across the U.S. Called GLEAM (NCT06294236), the study started enrolling up to…

A graphic prediction tool may accurately estimate the chance of survival over two years in people ANCA-associated vasculitis (AAV), according to a study at a single Chinese hospital. The tool, a nomogram based on 16 predictive factors, was able to differentiate patients who survived from those who didn’t with…

Physicians typically do not overestimate the overall health of people with ANCA-associated vasculitis (AAV), a study of global assessments made by patients and their doctors in Australia reports. In cases where ratings between these two groups markedly differed, doctors tended to assign a lower score than did the people…

Adicet Bio has pushed to the second half of 2025 the expected timing for enrolling patients with ANCA-associated vasculitis (AAV) in an ongoing Phase 1 clinical trial testing ADI-001, an experimental CAR T-cell therapy for a number of autoimmune diseases. The company had said it expected enrollment…

More than half of the people living with ANCA-associated vasculitis (AAV) have infections caused by bacteria, fungi, or viruses, often in the respiratory tract, with more than one-third developing severe infections. That’s according to a meta-analysis of published data, which also identified several risk factors for infections in this…

Q32 Bio is delaying the start of a planned Phase 2 clinical trial designed to test its ADX-097 therapy candidate in people with ANCA-associated vasculitis (AAV). The trial had been expected to begin in 2025. While details on that planned Phase 2 trial in AAV patients had…

Being frail, that is, more vulnerable to health stressors as a result of aging-related biological changes, may put older adults with ANCA-associated vasculitis (AAV) at higher risk of developing severe infections, a study in the U.S. suggests. Being age 75 or older, but not frail, was linked to a…

People with ANCA-associated vasculitis (AAV) who carry certain variants in SERPINA1 — a gene that’s been previously linked to the autoimmune disease — may have a six times higher risk of death than those without such variants. That’s according to new data from a single-center study in Brazil, in…

Low blood levels of glial fibrillary acidic protein (GFAP) are linked to more active disease and a higher risk of kidney failure in newly diagnosed ANCA-associated vasculitis (AAV), a study finds. The findings point to GFAP as a potential blood biomarker to predict the course of AAV early and…